Clinical Trials

MAP-CCTL019B2003I: Program Title: Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release of the out of specification product


Study ID
HUMC-Novartis-EAP-Pro2018-0751

NCT Number
(Click on the NCT number for more information about the trial)

Research Study Number
Pro2018-0751

Principle Investigator
Dr. Michele Donato

Phase
II

Sponsor
Novartis


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now